Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 22, 1992 - Issue 5
Submit an article Journal homepage
13
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors

Y. H. Park Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
,
R. Barker Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
,
B. Griffin Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
,
D. Barratt Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
,
M. Dupriest Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
,
K. Brazzell Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
,
B. York Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
&
P. Mayer Research and Development, Alcon Laboratories, Inc., Fort Worth, Texas, 76134, USA
 show all
Pages 543-550 | Received 13 Aug 1991, Accepted 22 Jan 1992, Published online: 22 Sep 2008

References

  • Brazzell R. K., Park Y. H., Wooldridge C. B., McCue B., Barker R., Couch R., York B. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metabolism and Disposition 1990; 18: 435–440
  • Brazzell R. K., Mayer P. R., Dobbs R., McNamara P. J., Teng R., Slattery J. T. Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man. Pharmaceutical Research 1991; 8: 112–118
  • Craig W. H., Welling P. G. Protein binding of antimicrobials. Clinical pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics 1977; 2: 252–268
  • Dvornik D. Aldose reductase inhibition. An Approach to the Prevention of Diabetic Complications, D. Porte. Biomedical Information Corp., McGraw-Hill, New York 1987
  • Gaudette L. E., Brodie B. B. Relationship between the lipid solubility of drugs and their oxidation by liver microsomes. Biochemical Pharmacology 1959; 2: 89–96
  • Goldstein A., Aronow L., Kalman S. M. Drug Metabolism. Principles of Drug Action; The Basis of Pharmacology, 2nd ed. John Wiley and Sons, New York 1974; 227–300
  • Griffin B. W., McNatt L. G. Characterization of the reduction of 3-acetylpyridine adenine dinucleotide phosphate by benzyl alcohol catalyzed by aldose reductase. Archives of Biochemistry and Biophysics 1986; 246: 75–81
  • Griffin B. W., McNatt L. G., Chandler M. L., York B. M. Effects of two new aldose reductase inhibitors, AL1567 and AL1576, in diabetic rats. Metabolism 1987; 36: 486–490
  • Hansch C. Quantitative relationships between lipophilic character and drug metabolism. Drug Metabolism Reviews 1972; 1: 1–14
  • Kador P. F. The role of aldose reductase in the development of diabetic complications. Medical Research Reviews 1988; 8: 325–352
  • Kador P. F., Kinoshita J. N., Sharpless N. E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. Journal of Medicinal Chemistry 1985; 28: 841–849
  • Lipinski C. A., Hutson N. J. Aldose reductase inhibitors as a new approach to the treatment of diabetic complications. Annual Report on Medicinal Chemistry 1984; 19: 169–177
  • McCue B. A., Park Y. H., Brazzell R. K., Boltralik J. J. Capillary gas chromatographic- electron capture assay for the aldose reductase inhibitor imirestat in lens and plasma. Journal of Chromatography 1991; 565: 255–264
  • Park Y. H., Mayer P., Brazzell K., York B., Barker R., McCue B., Mattern J., Stoltz M., Couch R. Comparative disposition studies of the aldose reductase inhibitors imirestat and AL3152. Third North American ISSX Meeting Abstract. 1990, 18
  • Park Y. H., Wooldridge C. B., Stoltz M. L., Brazzell R. K. Disposition of the aldose reductase inhibitor AL1576 in rats. Journal of Pharmaceutical Science 1988; 77: 110–115
  • Ritschel W. A., Hammer G. V. Prediction of the volume of distribution from in vitro data and use for estimating absolute extent of absorption. International Journal of Clinical Pharmacology, Therapy and Toxicology 1980; 18: 298–316
  • Polyol Pathway and its Role in Diabetic Complications, N. Sakamoto, J. H. Kinoshita, P. F. Kador, N. Hotta. Excerpta Medica, Amsterdam, New York, Oxford 1988
  • Toon S., Rowland M. Structure pharmacokinetic activity relationships with some tetracyclines. Journal of Pharmacy and Pharmacology 1979; 31(Suppl.)43
  • Toon S., Rowland M. Structure-pharmacokinetic relationships among the barbiturates in the rat. Journal of Pharmacology and Experimental Therapeutics 1983; 225: 752–763
  • Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (A1C) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Bio-pharmaceutics 1978; 6: 165–175

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.